BioMe Inc. and Yonsei Medical Center sign technology

SEOUL, South Korea, December 29, 2021 (GLOBE NEWSWIRE) – The microbiome treatment market is receiving global attention and is rapidly emerging as a new treatment alternative for various incurable diseases. However, recent reports of failed clinical trials and the limitation of identifying a clear mode of action require a cautious approach. Korean company BioMe Inc. wants to disrupt the process with breakthrough microbiome-based therapies.

Founded in November 2020 by Professor Sang Sun Yoon of the Department of Microbiology and Immunology, Yonsei University College of Medicine, BioMe Inc. has developed a living biotherapeutic product (LBP) based on the microbiome. Based on the prestigious microbiology research foundation of Yonsei University College of Medicine, BioMe Inc.

(i) understand the bacteriological characteristics of candidate strains,

(ii) can prove its effectiveness using animal disease models, made possible in Avison’s state-of-the-art biomedical research center.

To speed up its research and development process, the startup recently signed a technology transfer contract with Yonsei University College of Medicine. BioMe Inc. would begin developing microbiome-based therapies with the six patents transferred from Yonsei University College of Medicine.

The technology transfer under the contract includes a total of six patents, and BioMe’s development pipeline is as follows:

No. Development pipeline
1 A protein derived from the respiratory tract microbiome with inhibitory effects against broad-spectrum respiratory infections
2 An immune system boosting protein derived from the microbiome with a clear anticancer effect
3 An effective skin microbiome in the treatment of atopic dermatitis
4 A consortium of commensal microbes showing their effectiveness in treating inflammatory bowel disease
5 New symbiotic system inducing butyrate synthesis

In addition to the above technology, a new pipeline capable of degrading TMA, a risk factor for cardiovascular disease, is under development by BioMe Inc.

Beyond finding useful strains, BioMe Inc. is building a microbiome-based system that selectively produces beneficial metabolites or degrades their dangerous counterparts. This development strategy represented by “Molecule First” is implemented through the iBTSMT (Integrated BioMe Technology for Screen).

Recently, Kim Bu Seon, former Managing Director of SK Bioscience, was recruited to design target product profiles for candidate strains. Preclinical trials are expected to begin in the first half of 2022 and clinical trials will begin in 2023.

Press contact: [email protected]

Related images

Image 1: BioMe


This content was posted through the press release distribution service at

Comments are closed.